Literature DB >> 27028808

[The Biological Function of SHP2 in Human Disease].

S M Li1,2,3.   

Abstract

Tyrosyl phosphorylation participates in various pathological and physiological processes, which are regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). The Src homology-2 domain containing phosphatase SHP2 (encoded by PTPN11) is an important phosphatase, which was found to be implicated in the regulation of genetic disease, development, metabolic, neurological, muscle, skeletal disease and cancer. Germline mutations in PTPN11 cause the Noonan Syndrome, LEOPARD syndrome and metachondromatosis. Somatic PTPN11 mutations occur in hematologic malignancies and in solid tumors. SHP2 is also an important component in oncogenic signaling pathways. It may play different roles in different stages and positions of human cancers. Whether SHP2 is an oncogene or cancer suppressor gene remains to be elucidated. Elucidation of the regulatory mechanisms of SHP2 in human disease will provide new insights into disease and new targets for therapy. Here, we summarized the structural basis and recent research progression on SHP2 in various human disease, including genetic and cancer diseases.

Entities:  

Keywords:  SHP2; cancer cell; genetic disease; protein tyrosine phosphatases; signaling

Mesh:

Substances:

Year:  2016        PMID: 27028808     DOI: 10.7868/S0026898416010110

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  4 in total

Review 1.  Targeting SHP2 phosphatase in hematological malignancies.

Authors:  Rahul Kanumuri; Santhosh Kumar Pasupuleti; Sarah S Burns; Baskar Ramdas; Reuben Kapur
Journal:  Expert Opin Ther Targets       Date:  2022-05-03       Impact factor: 6.797

2.  Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.

Authors:  Zhidong Gu; Xuqian Fang; Chang Li; Changqiang Chen; Guangshu Liang; Xinming Zheng; Qishi Fan
Journal:  Int J Oncol       Date:  2017-06-23       Impact factor: 5.650

3.  SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo.

Authors:  ZhongQian Hu; Jia Li; Qi Gao; Shuping Wei; Bin Yang
Journal:  Onco Targets Ther       Date:  2017-08-02       Impact factor: 4.147

Review 4.  Strategies to overcome drug resistance using SHP2 inhibitors.

Authors:  Meng Liu; Shan Gao; Reham M Elhassan; Xuben Hou; Hao Fang
Journal:  Acta Pharm Sin B       Date:  2021-03-28       Impact factor: 11.413

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.